FDMT Competitors & Alternatives

Compare 4D Molecular Therapeutics Inc with similar stocks in the same industry

Biotechnology

FDMT

Main Stock
$11.65
-4.74%
Tradestie Score
52
Market Cap
$407.71M
Revenue Growth
45.1%
Analyst Upside
+141.1%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 1/10 Drug Discovery Biotech Gene Therapy
Competitive Moat: None
Core Technology Stack: directed evolution AAV capsids, intravitreal and aerosolized delivery
Major Customers 4
clinical trial sites specialty ophthalmology clinics pulmonology centers research hospitals
Critical Suppliers 4
AAV vector CDMOs CROs plasmid manufacturers raw material suppliers
Direct Ecosystem Rivals 5

Top Competitors

11 stocks in Biotechnology
Company Price Market Cap P/E Score Action
BMRN BioMarin Pharmaceuticals Inc
$58.32
+1.90%
$10.53B - 54 Compare
CRSP CRISPR Therapeutics AG
$40.61
-3.86%
$6.02B - 49 Compare
BEAM Beam Therapeutics Inc. Common Stock
$21.29
-6.75%
$2.44B - 41 Compare
SRPT Sarepta Therapeutics,, Inc. Common Stock
$15.14
-5.76%
$2.02B 802.5 41 Compare
STOK Stoke Therapeutics, Inc. Common Stock
$26.54
-0.52%
$1.29B - 54 Compare
CGEM Cullinan Therapeutics, Inc. Common Stock
$9.72
-5.45%
$354.45M - 47 Compare
ANNX Annexon, Inc. Common Stock
$3.59
-8.55%
$332.96M - 46 Compare
EDIT Editas Medicine, Inc. Common Stock
$1.91
-12.21%
$319.22M - 51 Compare
NKTX Nkarta, Inc. Common Stock
$1.21
+1.26%
$151.28M - 49 Compare
ALXO ALX Oncology Holdings Inc. Common Stock
$0.95
-9.07%
$96.93M - 60 Compare

Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2836)

11 stocks in this industry